Safety and Efficacy of DTX401 , an AAV8 ‐Mediated Liver‐Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a ( GSDIa )

Documenti analoghi

• Untargeted Proteomics Profiling of Liver and Plasma in Fed and Fasted Liver‐Specific Glycogen Storage Disease Type Ia ( GSD Ia) Mice: Toward Potential Protein Biomarkers
  di: Ruiqi Xiao, et al.
  Pubblicazione: (2026)
• Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning
  di: J. J. A. van den Dorpel, et al.
  Pubblicazione: (2024)
• The relation between dietary polysaccharide intake and urinary excretion of tetraglucoside
  di: Candelas Gross‐Valle, et al.
  Pubblicazione: (2024)
• Liver‐Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia
  di: Cheol Lee, et al.
  Pubblicazione: (2025)
• Myopathic Symptoms and Exercise Tolerance in Adolescent Patients With Long‐Chain Fatty Acid Oxidation Disorders
  di: Marit Schwantje, et al.
  Pubblicazione: (2025)